Our study also showed that patients belonging to HG-T experience comparably poor outcomes with anti-PD-1/anti-CTLA-4 combination therapy (COMBO; 34% objective response rate, OR = 3.64), which is also a frontline ICI therapy in MM. This evidence concerns the gene CTLA4 and Miyoshi myopathy.